NextBlue of North Dakota Medicare Advantage Important Announcement

NextBlue of North Dakota Medicare Advantage Plan would like to inform providers of a new part B drug which will require prior authorization as of August 1, 2024. The Federal Drug Administration (FDA) just approved HCPCS code J9999: Rytelo™ (imetelstat) to require prior approval effective on/after August 1, 2024.

The NextBlue Part B drug list will be updated shortly, which is located on the NextBlue Provider Website under Provider Resources | Prior Authorizations (nextbluend.com).

Questions?
Contact the NextBlue of North Dakota Provider Call Center at 1-844-753-8039.